News

The company said the variant is for the patients not taking chronic inhaled aminoglycoside antibiotics. If approved, Translarna would be the first oral protein restoration treatment that targets

In addition, GSK sold its marketed oncology portfolio to Novartis India. The transaction follows a worldwide transaction between their parent firms GSK and Novartis, which was completed earlier

APP-111 showed efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer. In preclinical studies, the drug appeared to have less peripheral

Under a collaboration and option agreement signed in June 2012, Liquidia was entitled to receive an upfront payment including cash and equity, R&D funding, and possible development milestones

The company has already started first of the facility expansions at various locations in Germany including its Ravensburg Vetter West center for visual inspection and logistics. Vetter completed

CADCA is asking our 5,000 community coalitions to spread the word to their communities that medicine abuse has become an epidemic. National Medicine Abuse Awareness Month promotes the

VTP-43742 is the Company’s wholly owned and first-in-class ROR?t inhibitor product candidate for the treatment of autoimmune disorders, potentially including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and

TruSight Tumor 15 is optimized for low input DNA from tissue preserved in formalin and paraffin. Illumina president Francis deSouza said: "In 2014, Illumina catalyzed the Actionable Genome

This final closing includes new strategic investments from AbbVie, WuXi PharmaTech, and Watson Fund. These new investors join the previously announced Accelerator IV syndicate, which includes Alexandria Venture